

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
FOSTER ET AL.

Art Unit: 1617
Examiner: Javanmard,
Sahar

INTERNATIONAL APPLICATION NO: PCT/EP2003/010579

FILED: 23 SEPTEMBER 2003

U.S. APPLICATION NO: 10/528,688

35 USC §371 DATE: 17 MAY 2005

FOR: SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS IN THE
TREATMENT OF DEMYELINATING DISORDERS

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed September 19, 2006. Since it is being filed in accordance with 37 C.F.R. §1.97(c), a letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-9273


Cozette McAvoy
Attorney for Applicants
Reg. No. 60,457

Date: *3rd October 2008*